Virtus Biotech ETF(BBP · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$87.25
- 52-Week Range
- $57.61 – $90.42
- YTD
- +9.50%
- IV Rank (30D)
- 15.42
- Straddle Price
- $6.20
- P/C Vol Ratio
- 1.00
Info
Virtus Biotech ETF (BBP) ETF
- Exchange
- ARCX
- Inception
- 2014-12-16
- Has Options
- Yes
ETF Profile
holdings as of 2026-10-31
Holdings
66
AUM
$44.9M
Provider
Unknown
Inception
2014-12-16
Exchange
ARCX
Data As Of
2026-10-31
Expense Ratio
—
Dividend Yield
—
Distribution
—
Asset Allocation
Top Holdings
top 50 of 66 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| — | DREYFUS GOVERNMENT CASH MANAGE | 4.17% | Short-term investment | US |
| IBRX | ImmunityBio Inc | 4.03% | Equity (common) | US |
| MIRM | Mirum Pharmaceuticals Inc | 2.42% | Equity (common) | US |
| MRNA | Moderna Inc | 2.28% | Equity (common) | US |
| DVAX | Dynavax Technologies Corp | 2.18% | Equity (common) | US |
| FOLD | Amicus Therapeutics Inc | 2.06% | Equity (common) | US |
| NVAX | Novavax Inc | 2.05% | Equity (common) | US |
| DAWN | Day One Biopharmaceuticals Inc | 2.03% | Equity (common) | US |
| AXSM | Axsome Therapeutics Inc | 1.89% | Equity (common) | US |
| ARDX | Ardelyx Inc | 1.89% | Equity (common) | US |
| BNTX | BioNTech SE | 1.83% | Equity (common) | DE |
| GILD | GILEAD SCIENCES INC | 1.80% | Equity (common) | US |
| IOVA | Iovance Biotherapeutics Inc | 1.77% | Equity (common) | US |
| HALO | HALOZYME THERAPEUTICS INC | 1.76% | Equity (common) | US |
| KRYS | Krystal Biotech Inc | 1.74% | Equity (common) | US |
| AMGN | Amgen Inc | 1.64% | Equity (common) | US |
| ONC | BeOne Medicines Ltd | 1.62% | Equity (common) | US |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 1.62% | Equity (common) | US |
| VALU | Kiniksa Pharmaceuticals Intern | 1.61% | Equity (common) | US |
| INCY | INCYTE CORP | 1.60% | Equity (common) | US |
| VALU | THERAVANCE BIOPHARMA INC | 1.59% | Equity (common) | KY |
| VRTX | VERTEX PHARMACEUTICALS INC | 1.58% | Equity (common) | US |
| BIIB | BIOGEN INC | 1.57% | Equity (common) | US |
| BBIO | Bridgebio Pharma Inc | 1.57% | Equity (common) | US |
| ASND | Ascendis Pharma A/S | 1.56% | Equity (common) | DK |
| IONS | IONIS PHARMACEUTICALS INC | 1.56% | Equity (common) | US |
| LGND | LIGAND PHARMACEUTICALS | 1.54% | Equity (common) | US |
| EXEL | EXELIXIS INC | 1.54% | Equity (common) | US |
| GERN | Geron Corp | 1.53% | Equity (common) | US |
| AGIO | AGIOS PHARMACEUTICALS INC | 1.53% | Equity (common) | US |
| REGN | REGENERON PHARMACEUTICALS | 1.52% | Equity (common) | US |
| PTCT | PTC Therapeutics Inc | 1.52% | Equity (common) | US |
| SNDX | Syndax Pharmaceuticals Inc | 1.52% | Equity (common) | US |
| CRNX | Crinetics Pharmaceuticals Inc | 1.51% | Equity (common) | US |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.51% | Equity (common) | US |
| VALU | Roivant Sciences Ltd | 1.49% | Equity (common) | US |
| UTHR | UNITED THERAPEUTICS CORP | 1.45% | Equity (common) | US |
| SRPT | SAREPTA THERAPEUTICS INC | 1.44% | Equity (common) | US |
| PHAT | Phathom Pharmaceuticals Inc | 1.43% | Equity (common) | US |
| TGTX | TG Therapeutics Inc | 1.43% | Equity (common) | US |
| ZLAB | Zai Lab Ltd | 1.42% | Equity (common) | CN |
| ACAD | ACADIA Pharmaceuticals Inc | 1.41% | Equity (common) | US |
| KALV | KalVista Pharmaceuticals Inc | 1.41% | Equity (common) | US |
| AUPH | Aurinia Pharmaceuticals Inc | 1.40% | Equity (common) | CA |
| RYTM | Rhythm Pharmaceuticals Inc | 1.37% | Equity (common) | US |
| HRMY | Harmony Biosciences Holdings I | 1.37% | Equity (common) | US |
| APLS | Apellis Pharmaceuticals Inc | 1.36% | Equity (common) | US |
| TVTX | Travere Therapeutics Inc | 1.36% | Equity (common) | US |
| NBIX | NEUROCRINE BIOSCIENCES INC | 1.36% | Equity (common) | US |
| IMCR | Immunocore Holdings PLC | 1.35% | Equity (common) | GB |
Geographic Breakdown
Fund Holdings
Virtus LifeSci Biotech Products ETF ·
NPORT-P period 2026-10-31
(filed 2026-03-31)
Net assets:
$45M
· 66 total positions
· equity 99.37%
· non-equity 4.17%
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | ImmunityBio Inc | ImmunityBio Inc | 4.03% | $1.8M |
| 2 | Mirum Pharmaceuticals Inc | Mirum Pharmaceuticals Inc | 2.42% | $1.1M |
| 3 | Moderna Inc | Moderna Inc | 2.28% | $1.0M |
| 4 | Dynavax Technologies Corp | Dynavax Technologies Corp | 2.18% | $979860 |
| 5 | Amicus Therapeutics Inc | Amicus Therapeutics Inc | 2.06% | $925663 |
| 6 | Novavax Inc | Novavax Inc | 2.05% | $920048 |
| 7 | Day One Biopharmaceuticals Inc | Day One Biopharmaceuticals Inc | 2.03% | $912297 |
| 8 | Axsome Therapeutics Inc | Axsome Therapeutics Inc | 1.89% | $849577 |
| 9 | Ardelyx Inc | Ardelyx Inc | 1.89% | $846269 |
| 10 | BioNTech SE | BioNTech SE | 1.83% | $819796 |
| 11 | GILEAD SCIENCES INC | GILEAD SCIENCES INC | 1.80% | $805566 |
| 12 | Iovance Biotherapeutics Inc | Iovance Biotherapeutics Inc | 1.77% | $792135 |
| 13 | HALOZYME THERAPEUTICS INC | HALOZYME THERAPEUTICS INC | 1.76% | $787663 |
| 14 | Krystal Biotech Inc | Krystal Biotech Inc | 1.74% | $779638 |
| 15 | Amgen Inc | Amgen Inc | 1.64% | $735042 |
| 16 | BeOne Medicines Ltd | BeOne Medicines Ltd | 1.62% | $728754 |
| 17 | BIOMARIN PHARMACEUTICAL INC | BIOMARIN PHARMACEUTICAL INC | 1.62% | $724730 |
| 18 | Kiniksa Pharmaceuticals International Plc | Kiniksa Pharmaceuticals Intern | 1.61% | $721693 |
| 19 | INCYTE CORP | INCYTE CORP | 1.60% | $716701 |
| 20 | THERAVANCE BIOPHARMA INC | THERAVANCE BIOPHARMA INC | 1.59% | $712352 |
| 21 | VERTEX PHARMACEUTICALS INC | VERTEX PHARMACEUTICALS INC | 1.58% | $710019 |
| 22 | BIOGEN INC | BIOGEN INC | 1.57% | $705708 |
| 23 | Bridgebio Pharma Inc | Bridgebio Pharma Inc | 1.57% | $702616 |
| 24 | Ascendis Pharma A/S | Ascendis Pharma A/S | 1.56% | $700910 |
| 25 | IONIS PHARMACEUTICALS INC | IONIS PHARMACEUTICALS INC | 1.56% | $698892 |
Showing top 25 of 65 equity holdings.
Non-equity holdings
— 1 positions,
4.17% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 4.17% | $1.9M | 1 |
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -1.55% | 6 |
| Feb | -0.96% | 6 |
| Mar | +0.10% | 6 |
| Apr | -1.60% | 6 |
| May | -0.61% | 6 |
| Jun | +2.65% | 6 |
| Jul | +3.03% | 5 |
| Aug | -0.07% | 5 |
| Sep | -2.93% | 5 |
| Oct | +0.98% | 5 |
| Nov | +0.92% | 5 |
| Dec | +0.97% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $85.64
SMA 50: $85.95
SMA 200: $79.58
Current: $87.16
EMA 12: $85.77
EMA 26: $85.81
MACD: -0.0343 | Signal: 0.0783
BEARISH
ADX (14): 11.90
RANGE
+DI: 32.42
−DI: 23.72
Momentum Oscillators
RSI (14): 54.68
NEUTRAL
Stoch %K: 65.59
Stoch %D: 52.46
Williams %R: -16.74
Volume & Volatility
BB Upper: $88.06
BB Lower: $83.22
NEUTRAL
OBV: 233,418
Vol SMA 20: 6,181
Vol ROC: -51.16%
ATR: $1.64
True Range: $1.25
HV 20: 26.0%
HV 30: 27.0%
HV 60: 28.2%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:10.043000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Options Activity
- IV Rank (30D)
- 15.42
- IV Rank (7D)
- 50.81
- Avg IV
- 31.2%
- Straddle (30D)
- $6.20
- Straddle (7D)
- $2.50
- P/C Volume
- 1.00
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.01
- Correlation (SPY)
- 51.7%
- R²
- 0.27
- Ann. Volatility
- 24.0%
- SPY Volatility
- 12.3%
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Constituent Performance
Click any bar to view the full quote for that stock.
Constituents
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|